Taxol, derived from the plant alkaloid paclitaxel, is a prominent anticancer agent. It acts by inhibiting microtubule formation and preventing cancer cell division. The intravenous administration of Taxol has been well established, particularly in the treatment of solid tumors. However, prolonged use of the drug often leads to reduced efficacy due to the emergence of resistance in cancer cells. Furthermore, the side effects of Taxol can vary depending on individual factors such as age, genetics, and general health. To overcome these challenges, researchers have investigated various formulations, including nanocomplexes, to address drug resistance and minimize adverse effects. These developments have shown promise in improving Taxol’s therapeutic effectiveness. In addition to its primary use in oncology, Taxol has also been investigated for its potential in other medical fields, expanding its clinical applications. This editorial highlights the importance of Taxol in cancer treatment and emphasizes the need for ongoing research to combat resistance and expand its use in contemporary medicine.
